Full Press Release Details
and Controlled Entities (Mesoblast Group)
HALF-YEAR INFORMATION
FOR THE SIX MONTHS ENDED 31 DECEMBER 2015
PROVIDED TO THE ASX UNDER LISTING RULE 4.2A
This half-year financial report is to be read in conjunction with the financial report for the
period ended 30 June 2015.
Half-Year Report for the six months to
| Report for the half-year ended | 31 December 2015 | |
| Previous corresponding period is the financial year ended and half-year ended | 30 June 2015 31 December 2014 |
This report has been prepared in U.S. dollars (US$) being the legal
currency of the United States of America. All amounts are presented in US$ in thousands unless stated otherwise.
| Up/down | % change | Amount reported for the half-year ended 31 December 2015 (US$ in thousands) | ||||||||||||||
| Revenues (item 2.1) | Up | 2% | to | 11,527 | ||||||||||||
| Loss from ordinary activities after tax attributable to members (item 2.2) | Down * | 18% | to | 35,485 | ||||||||||||
| Net loss for the period attributable to members (item 2.3) | Down * | 18% | to | 35,485 |
There are no dividends being proposed or declared for the period (item 2.4)
Date for determining entitlements to the dividends: N/A (item 2.5)
Brief explanation of any of the figures reported above necessary to enable the figures to be understood (item 2.6):
Please refer to the Directors Report (please see the section titled Management s Discussion and Analysis of Financial
Condition and Results of Operations on page 28 of the attached Form 6-K) and the accompanying press release.
Net tangible (liability) /
asset backing per ordinary security
| 31 December 2015 | 31 December 2014 | |
| (2.13) cents | (6.47) cents |
A large proportion of the
company s assets are intangible in nature, consisting of intellectual property and goodwill relating to the acquisition of Mesoblast, Inc and the Mesenchymal Stem Cells (MSCs) technology. These assets are excluded from the calculation of net
tangible assets per security. Our total deferred tax liability has also been excluded from the calculation to the extent it relates to future tax obligations as a result of the intellectual property assets deriving revenue at some point in the
future. This deferred tax liability has arisen as a direct result of the intellectual property being acquired.
The financial information provided in
the Appendix 4D should be read in conjunction with the Quarterly Report on Form 6-K (incorporating the Half-Year Report) for the three and six months ended December 31, 2015 (attached) which has been
prepared in accordance with Australian Accounting Standards.
Directors Report - please refer to the section titled
Management s Discussion and Analysis of Financial Condition and Results of Operations on page 28 of the attached Form 6-K.
Statement please refer to the Financial Statements on page 5 of the attached Form 6-K.
The financial report has been independently
reviewed. The financial report is not subject to a qualified independent review statement. The independent audit review report is attached to the financial statements.